Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk

Atherosclerosis
C P PalazónL Badimon

Abstract

The use of lipid-lowering drugs has been shown to have beneficial effects in primary and secondary prevention of cardiovascular disease. Gemfibrozil has shown beneficial effects as a lipid lowering agent; however, some proactivating effects on platelet function in vitro have been described. We have studied in a porcine model of atherosclerosis if gemfibrozil could prevent the early vascular effects of a cholesterol-rich diet without inducing platelet activation and, hence, mural thrombosis. Pigs were fed for 50 days with a diet rich in saturated fat and cholesterol (cho). The longitudinal follow-up study showed that in control animals LDL-cho increased significantly up to 181.9 +/- 34.2 mg/dl or 79% of total-cho, while HDL-cho was reduced to 19% of total-cho. Gemfibrozil, at average therapeutic plasma levels (peak levels of 28 micrograms/ml) [corrected], induced a significant reduction in the relative amount of LDL (P < 0.05) and increased HDL (P < 0.05). The increase in fibrinogen plasma levels observed in the control group due to the dietary intervention (+25%) was prevented in the treated animals (-5%). In treated animals, vascular lesions were significantly less severe, platelet deposition upon exposure of damaged vessel wa...Continue Reading

References

Jan 30, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Jan 1, 1990·Journal of Clinical Pharmacology·S C ForlandR E Cutler
Jul 5, 1990·Klinische Wochenschrift·H KnaufE Mutschler
Mar 1, 1989·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·L BadimonV Fuster
May 1, 1986·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·L BadimonV Fuster
Jan 1, 1985·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·V FusterE J Bowie
May 15, 1982·Thrombosis Research·J R O'BrienF C Goodland
Apr 1, 1993·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·P M TymkewyczP J Gaffney
Jan 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·A BröijersénP Hjemdahl
Nov 9, 2004·Atherosclerosis. Supplements·T R PedersenUNKNOWN Scandinavian Simvastatin Survival Study Group

❮ Previous
Next ❯

Citations

Oct 13, 2000·European Journal of Clinical Investigation·T RoyoL Badimon
Feb 19, 2000·Current Opinion in Lipidology·G F Watts, S B Dimmitt
Jan 1, 2012·GigaScience·Xiaodong FangYutao Du
Jan 29, 2011·Journal of Biomedicine & Biotechnology·Gemma VilahurLina Badimon
Jul 8, 2015·Journal of Thrombosis and Haemostasis : JTH·T G MastenbroekJ M E M Cosemans
Sep 17, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Cristina RodríguezLina Badimon
Jul 12, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Andrew J MurphyJaye Chin-Dusting
Mar 5, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Paul CullenUNKNOWN MAFAPS Consortium
Aug 1, 2006·Pathophysiology of Haemostasis and Thrombosis·Patrizia FerroniGiovanni Davì
Nov 27, 2019·British Journal of Pharmacology·Ioanna AndreadouPéter Ferdinandy
Jul 22, 2018·Journal of the American Chemical Society·Zhe ZhuangJin-Quan Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.